Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma

Zanubrutinib (BGB-3111) is a next-generation Bruton tyrosine kinase inhibitor designed to be more selective with fewer off-target effects. We conducted a phase 1 study to assess the safety of its combination with obinutuzumab and evaluate early efficacy in 81 patients with chronic lymphocytic leukem...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Blood Adv
मुख्य लेखकों: Tam, Constantine S., Quach, Hang, Nicol, Andrew, Badoux, Xavier, Rose, Hannah, Prince, H. Miles, Leahy, Michael F., Eek, Richard, Wickham, Nicholas, Patil, Sushrut S., Huang, Jane, Prathikanti, Radha, Cohen, Aileen, Elstrom, Rebecca, Reed, William, Schneider, Jingjing, Flinn, Ian W.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Society of Hematology 2020
विषय:
Clinical Trials and Observations
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7556127/
https://ncbi.nlm.nih.gov/pubmed/33022066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002183
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन